metricas
covid
Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Antiangiogenic therapy in Sorsby's fundus dystrophy without a mutation in the TI...
Journal Information
Vol. 88. Issue 6.
Pages 240-243 (June 2013)
Share
Share
Download PDF
More article options
Visits
1687
Vol. 88. Issue 6.
Pages 240-243 (June 2013)
Short communication
Antiangiogenic therapy in Sorsby's fundus dystrophy without a mutation in the TIMP-3 gene
Tratamiento antiangiogénico en fondo de distrofia de Sorsby sin mutación en gen de TIMP-3
Visits
1687
S. Copete-Piqueras
Corresponding author
sergioab@hotmail.com

Corresponding author.
, C. Cava-Valenciano, I. Flores-Moreno, A. Moreno-Valladares, V. Bautista Ruescas
Servicio de Oftalmología, Complejo Hospitalario Universitario de Albacete, Albacete, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (6)
Show moreShow less
Abstract
Case report

The case is presented of a 32-year-old man referring to metamorphopsia and blurred vision in both eyes for 3 days. Best corrected visual acuity of 20/32 was found in the right eye and 20/25 in the left eye. Fundus examination revealed the presence of drusen-like deposits, suggestive of Sorsby's fundus dystrophy (SFD) and choroidal neovascularization (CNV) bilaterally. The patient received intravitreal ranibizumab. Visual acuity improved to 20/20 in both eyes at 6-month follow-up, and results of fundus examination showed complete regression of neovascularization. No mutations were found in the TIMP-3 gene.

Discussion

The known mutations in TIMP-3 may not be extended to all patients with SFD. The use of intravitreal ranibizumab may be considered as a therapeutic option in CNV secondary to SFD.

Keywords:
Sorsby's fundus dystrophy
TIMP-3
Antiangiogenic therapy
Choroidal neovascularization
Optical coherence tomography
Auto-fluorescence
Resumen
Caso clínico

Varón de 32 años, con metamorfopsias y visión borrosa bilateral de tres días de evolución. Mejor agudeza visual corregida de 20/32 en OD y 20/25 en OI. La funduscopia presenta lesiones amarillentas difusas sugerentes de distrofia de Sorsby y membranas neovasculares (MNV). Recibió tratamiento con ranibizumab intravítreo, mejorando la agudeza visual a 20/20 en ambos ojos y remitiendo las MNV. No se hallaron mutaciones conocidas de TIMP-3.

Discusión

Las mutaciones conocidas en TIMP-3 pueden no estar extendidas a todos los pacientes con fondo de distrofia de Sorsby. El ranibizumab intravítreo debe considerarse para el tratamiento de MNV secundaria a esta enfermedad.

Palabras clave:
Distrofia de Sorsby
TIMP-3
Tratamiento antiangiogénico
Membrana neovascular
Tomografía de coherencia óptica
Autofluorescencia

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos